Adaptive radiation after prostate surgery to lower side effects
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a precise, short-course radiation treatment (stereotactic body radiotherapy) after prostate removal surgery that adapts to your body each day to reduce side effects. It is for people whose prostate cancer has high-risk features or a rising PSA after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have had surgery to remove your prostate for prostate cancer
- Have at least one high-risk feature (like a positive margin, a rising PSA above 0.03, intermediate/high Decipher score, or cancer in lymph nodes)
- Be 18 years or older and in generally good health (KPS 70+ or ECOG 0-1)
- Be able to get a CT and MRI of the pelvis (or a special MRI if needed) within the past 4 months
- Not have cancer that has spread to distant organs, certain types of prostate cancer, or a history of inflammatory bowel disease or ataxia telangiectasia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radiation technique to better protect erectile function during prostate cancer treatment. It uses advanced imaging to precisely target the tumor while reducing harm to nearby structures.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial studies a targeted, high-intensity radiation approach given after prostate removal surgery when prostate cancer seems to be coming back locally. It may help control the disease in the pelvis while avoiding treatment that could cause more side effects.
This trial tests a shorter, stronger course of radiation (hypofractionated radiotherapy) given after prostate removal surgery. It may help people whose PSA levels rise again after surgery, aiming to reduce side effects and improve outcomes.
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) for men who have already had their prostate removed and still have signs of cancer (like rising PSA). The goal is to see if this can help prevent the cancer from coming back.
This trial studies a “daily adaptive” way of planning and delivering radiation after prostate surgery to treat prostate cancer that is coming back locally. It may help target the tumor more precisely while limiting radiation to healthy tissue.
Hear when a new Prostate Cancer (CRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.